Ovarian Cancer is the leading cause of death among all gynecologic malignancies, with more than 70% of women presenting with advanced-stage disease. As one of the most common types of protein modification, glycosylation has become a new hallmark of cancer. Several functions play a major role in carcinogenesis, including cell-matrix interaction, cell signaling and communication, tumor angiogenesis, immune modulation, and tumor metastasis. The genes involved in the glycosylation pathways include glycogenes or genes associated with glycan synthesis. Several studies support that cancer displays an aberrant expression of those glycogenes implicated in glycosylation; and certainly, changes in the expression of glycogenes or cell surface glycans have been related to cancer progression and prognosis. Aberrant glycan expression is caused by dysregulation of glycogene expression in cancer, thereby promoting tumorigenesis.
Fig.1 The functions of glycogen mobilization. (Dauer & Lengyel, 2019)
CD BioGlyco specializes in Cancer Glycogene research, providing customized glycogene discovery services in ovarian cancer. Our services are as follows:
Fig.2 Glycogene discovery methods in ovarian cancer. (CD BioGlyco)
CD BioGlyco specializes in cancer glycogene research to provide clients with first-class solutions. If you need attentive service, please feel free to contact us for more details.